Telix Pharmaceuticals (TLX1N) Stock Statistics & Valuation Metrics
Total Valuation
Telix Pharmaceuticals has a market cap or net worth of MXN 59.00B. The enterprise value is MXN 6.39B.
- Market Cap
- MXN 59.00B
- Enterprise Value
- MXN 6.39B
Share Statistics
Telix Pharmaceuticals has 340,331,480 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 340,331,480
- Owned by Insiders
- 6.32%
- Owned by Institutions
- 6.52%
Financial Efficiency
Telix Pharmaceuticals’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.86%.
- Return on Equity (ROE)
- -0.02
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- 1.86%
- Return on Capital Employed (ROCE)
- 0.02
- Revenue Per Employee
- 708.95K
- Profits Per Employee
- -6,284.325
- Employee Count
- 1,152
- Asset Turnover
- 0.69
- Inventory Turnover
- 10.32
Valuation Ratios
The current PE Ratio of Telix Pharmaceuticals is 96.54. Telix Pharmaceuticals’s PEG ratio is -0.43.
- PE Ratio
- 96.54
- PS Ratio
- 3.54
- PB Ratio
- 6.42
- Price to FCF
- -53.63
- Price to Operating Cash Flow
- -234.43
- PEG Ratio
- -0.43
Income Statement
In the last 12 months, Telix Pharmaceuticals had revenue of 816.72M and earned -7.24M in profits. Earnings per share was -0.02.
- Revenue
- 816.72M
- Gross Profit
- 433.78M
- Operating Income
- 18.05M
- Pretax Income
- -5.35M
- Net Income
- -7.24M
- EBITDA
- 40.18M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -13.35M and capital expenditures -45.11M, giving a free cash flow of -58.47M billion.
- Operating Cash Flow
- -13.35M
- Free Cash Flow
- -58.47M
- Free Cash Flow per Share
- -0.17
Dividends & Yields
Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.86%
- Earnings Yield
- 1.04%
Stock Price Statistics
- Beta
- -0.80
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 302.55
- 200-Day Moving Average
- 302.55
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Telix Pharmaceuticals upcoming earnings date is Feb 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 19, 2026
- Next Earnings Date
- Feb 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Telix Pharmaceuticals as a current ratio of 1.43, with Debt / Equity ratio of 112.34%
- Current Ratio
- 1.43
- Quick Ratio
- 1.27
- Debt to Market Cap
- 0.11
- Net Debt to EBITDA
- 8.09
- Interest Coverage Ratio
- 0.48
Taxes
In the past 12 months, Telix Pharmaceuticals has paid 1.89M in taxes.
- Income Tax
- 1.89M
- Effective Tax Rate
- -0.35
Enterprise Valuation
Telix Pharmaceuticals EV to EBITDA ratio is 114.20, with an EV/FCF ratio of -59.24.
- EV to Sales
- 3.91
- EV to EBITDA
- 114.20
- EV to Free Cash Flow
- -59.24
- EV to Operating Cash Flow
- -259.37
Balance Sheet
Telix Pharmaceuticals has MXN 251.80M in cash and marketable securities with MXN 579.61M in debt, giving a net cash position of -MXN 327.81M billion.
- Cash & Marketable Securities
- MXN 251.80M
- Total Debt
- MXN 579.61M
- Net Cash
- -MXN 327.81M
- Net Cash Per Share
- -MXN 0.96
- Tangible Book Value Per Share
- -MXN 0.29
Margins
Gross margin is 52.14%, with operating margin of -0.78%, and net profit margin of 3.69%.
- Gross Margin
- 52.14%
- Operating Margin
- -0.78%
- Pretax Margin
- 3.19%
- Net Profit Margin
- 3.69%
- EBITDA Margin
- 3.43%
- EBIT Margin
- -0.78%
Analyst Forecast
The average price target for Telix Pharmaceuticals is MXN 327.72, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- MXN 327.72
- Price Target Upside
- 8.32% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- 21.03%
- EPS Growth Forecast
- 165.12%
Scores
- Smart Score
- 10
- AI Score
- ―
